Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
59
KOD Quote, Financials, Valuation and Earnings
Last price:
$26.02
Seasonality move
:
-18.82%
Day range:
$25.64 - $28.00
52-week range:
$1.92 - $28.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
67.00x
Volume:
3M
Avg. volume:
859.1K
1-year change:
199.54%
Market cap:
$1.6B
Revenue:
--
EPS (TTM):
-$4.12
Analysts' Opinion
-
Consensus RatingKodiak Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $21.29, Kodiak Sciences, Inc. has an estimated downside of -18.13% from its current price of $26.00.
-
Price Target UpsideAccording to analysts, the highest upside price target is $40.00 representing -100% upside increase from its current price of $26.00.
Fair Value
-
According to the consensus of 7 analysts, Kodiak Sciences, Inc. has -18.13% downside to fair value with a price target of $21.29 per share.
KOD vs. S&P 500
-
Over the past 5 trading days, Kodiak Sciences, Inc. has overperformed the S&P 500 by 9.09% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kodiak Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kodiak Sciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kodiak Sciences, Inc. reported revenues of --.
Earnings Growth
-
Kodiak Sciences, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Kodiak Sciences, Inc. reported earnings per share of -$1.16.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.49x
EV / Free cash flow:
-13.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$26.5M
Return On Assets:
-73.38%
Net Income Margin (TTM):
--
Return On Equity:
-201.8%
Return On Invested Capital:
-78.9%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$22.6M | -$26.7M | -$26.5M | -$6.7M | -$6.5M | |
| Operating Income | -$288M | -$204M | -$221.2M | -$46.6M | -$62.4M | |
| EBITDA | -$265.4M | -$177.4M | -$194.7M | -$39.9M | -$55.8M | |
| Diluted EPS | -$5.18 | -$3.65 | -$4.12 | -$0.84 | -$1.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $805.5M | $544.7M | $350.9M | $202.5M | $75.7M | |
| Total Assets | $958.2M | $724M | $547.7M | $372.7M | $218.1M | |
| Current Liabilities | $54.4M | $65.6M | $70.8M | $24.1M | $42.4M | |
| Total Liabilities | $231.9M | $244.5M | $245.2M | $187.3M | $194.4M | |
| Total Equity | $726.3M | $479.5M | $302.4M | $185.4M | $23.7M | |
| Total Debt | $177.3M | $178.7M | $174.5M | $163.2M | $150.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$177M | -$119.5M | -$126.7M | -$21.2M | -$32.9M | |
| Cash From Investing | $344M | -$28.4M | -$587K | -$205K | -$60K | |
| Cash From Financing | $252K | -$27K | $1.5M | -- | $813K | |
| Free Cash Flow | -$196.6M | -$147.2M | -$127.3M | -$21.4M | -$32.9M | |
KOD
Sector
Market Cap
$1.6B
$27.9M
Price % of 52-Week High
90.31%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
0.14%
-1.49%
1-Year Price Total Return
199.54%
-16.66%
Beta (5-Year)
2.684
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$24.88
200-day SMA
Buy
Level
$9.68
Bollinger Bands (100)
Buy
Level
9.69 - 21.19
Chaikin Money Flow
Buy
Level
12.8M
20-day SMA
Buy
Level
$23.86
Relative Strength Index (RSI14)
Buy
Level
62.98
ADX Line
Buy
Level
34.55
Williams %R
Neutral
Level
-38.2716
50-day SMA
Buy
Level
$20.16
MACD (12, 26)
Buy
Level
1.66
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
19.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.1586)
Sell
CA Score
(Annual)
Level (-2.4847)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.5597)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Stock Forecast FAQ
In the current month, KOD has received 4 Buy ratings 2 Hold ratings, and 1 Sell ratings. The KOD average analyst price target in the past 3 months is $21.29.
-
Where Will Kodiak Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kodiak Sciences, Inc. share price will drop to $21.29 per share over the next 12 months.
-
What Do Analysts Say About Kodiak Sciences, Inc.?
Analysts are divided on their view about Kodiak Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kodiak Sciences, Inc. is a Sell and believe this share price will rise from its current level to $2.00.
-
What Is Kodiak Sciences, Inc.'s Price Target?
The price target for Kodiak Sciences, Inc. over the next 1-year time period is forecast to be $21.29 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is KOD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kodiak Sciences, Inc. is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KOD?
You can purchase shares of Kodiak Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kodiak Sciences, Inc. shares.
-
What Is The Kodiak Sciences, Inc. Share Price Today?
Kodiak Sciences, Inc. was last trading at $26.02 per share. This represents the most recent stock quote for Kodiak Sciences, Inc.. Yesterday, Kodiak Sciences, Inc. closed at $26.00 per share.
-
How To Buy Kodiak Sciences, Inc. Stock Online?
In order to purchase Kodiak Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KOD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KOD
Sector
P/E ratio
--
23.85x
PEG ratio
-0.49x
-0.01x
P/B ratio
67.00x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
KOD
Sector
Revenue growth
--
4.62%
Earnings growth
-39.2%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.68
-$0.21
Profitability
KOD
Sector
Profitability FY 2024
-$26.7M
$3.6M
Return on invested capital
-78.9%
-31.87%
Return on assets
-73.38%
-28.18%
Return on equity
-201.8%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
KOD
Sector
Total cash
$72M
$26.4M
Short term investments
--
$25.7M
Total assets
$335.6M
$76.9M
Long term debt
$150.4M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
